FcRn Inhibitors Redefining Multi-Indication Drug Development Strategies
The autoimmune treatment paradigm has been fundamentally transformed through the successful commercialization of Argenx's VYVGART, which achieved the historic milestone of becoming the first FcRn inhibitor to gain regulatory approval and market access. This innovative therapeutic solution has delivered exceptional clinical performance in generalized myasthenia gravis (gMG) management while...
0 Commentaires
0 parts